Literature DB >> 31508783

Surveillance of multidrug-resistant bacteria in pediatric and neonatal intensive care units in Rio de Janeiro State, Brazil.

Patrícia Mouta Nunes de Oliveira1, Sibelle Nogueira Buonora1, Cristina Letícia Passos Souza2, Robinson Simões Júnior2, Thais Carolina da Silva2, Gabriel José Teixeira Bom2, Caio Henrique da Silva Teixeira2, André Ricardo Araujo da Silva3.   

Abstract

INTRODUCTION: Multi-drug-resistant bacteria surveillance (MDR) systems are used to identify the epidemiology of MDR bacteria in neonates and children. This study aimed to describe the patterns by which MDR bacteria colonize and infect neonatal (NICU) and pediatric intensive care unit (PICU) patients in the state of Rio de Janeiro State, Brazil.
METHODS: A cross-sectional survey was performed using electronic data on NICU and PICU patients reported to the Rio de Janeiro State MDR bacteria surveillance system. All healthcare institutions that reported at least one case during the study period were included.
RESULTS: Between 2014 and 2017, 10,210 MDR bacteria cases, including 9261 colonizations and 949 infections, were reported. Among the colonizations, 5379 occurred in NICUs and 3882 in PICUs, while 405 infections occurred in NICUs and 544 in PICUs. ESBL producing Klebsiella sp and E. coli were the most reported colonization-causing agents in NICUs (1983/5379, 36.9%) and PICUs (1494/3882; 38.5%). The main causing bacteria reported in catheter-associated bloodstream infection (CLABSI), ventilator associated pneumonia, and catheter-associated urinary tract infection in NICUs were Klebsiella sp and E.coli (56/156, 35.9%), carbapenem-resistant Gram-negative bacteria (CRGNB) (22/65, 33.9%), and CRGNB (11/36, 30.6%) respectively, while in PICUs, they were MRSA (53/169, 31.4%), CRGNB (50/87, 57.4%), Klebsiella sp and E.coli (18/52, 34.6%), respectively.
CONCLUSIONS: MDR Gram-negative bacteria (ESBL producers and carbapenem-resistant bacteria) were the most reported agents among MDR bacteria reported to Rio de Janeiro surveillance system. Except for CLABSI in children, they caused all device-associated infections in NICUs and PICUs.

Entities:  

Mesh:

Year:  2019        PMID: 31508783     DOI: 10.1590/0037-8682-0205-2019

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  5 in total

1.  Predictors of Mortality in Patients with Carbapenem-Resistant Gram-Negative Bacilli or Vancomycin-Resistant Enterococci Bacteremia.

Authors:  Hye Jin Shi; Jin Seo Lee; Yong Kyun Cho; Joong Sik Eom
Journal:  Infect Drug Resist       Date:  2020-10-09       Impact factor: 4.003

2.  Effect of cefoperazone sulbactam sodium combined with meropenem on the immune function in the treatment of neonatal pneumonia caused by multidrug-resistant bacteria.

Authors:  Mingjing Lin; Shuxia Zhu; Haimei Weng; Yi Zhu
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

3.  Virulence Factors Found in Nasal Colonization and Infection of Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates and Their Ability to Form a Biofilm.

Authors:  Thamiris Santana Machado; Felipe Ramos Pinheiro; Lialyz Soares Pereira Andre; Renata Freire Alves Pereira; Reginaldo Fernandes Correa; Gabriela Coutinho de Mello; Tainara Aparecida Nunes Ribeiro; Bruno Penna; Daniela Sachs; Fábio Aguiar-Alves
Journal:  Toxins (Basel)       Date:  2020-12-25       Impact factor: 4.546

4.  Factors associated with multidrug-resistant bacteria in healthcare-associated infections: a pediatric intensive care unit case-control study.

Authors:  Barbara Barduchi Oliveira da Silva; Moacyr Silva Júnior; Fernando Gatti de Menezes; Eduardo Juan Troster
Journal:  Einstein (Sao Paulo)       Date:  2022-04-22

5.  Multidrug-Resistant Bacteria Isolated from Blood Culture Samples in a Moroccan Tertiary Hospital: True Bacteremia or Contamination?

Authors:  Soumia Nachate; Salma Rouhi; Hicham Ouassif; Hind Bennani; Abdelhamid Hachimi; Youssef Mouaffak; Said Younous; Fatiha Bennaoui; Nadia El Idrissi Slitine; Fadl Mrabih Rabou Maoulainine; Asmae Lamrani Hanchi; Nabila Soraa
Journal:  Infect Drug Resist       Date:  2022-09-27       Impact factor: 4.177

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.